NO20083856L - Piperidinderivater som CXCR3-reseptorantagonister - Google Patents
Piperidinderivater som CXCR3-reseptorantagonisterInfo
- Publication number
- NO20083856L NO20083856L NO20083856A NO20083856A NO20083856L NO 20083856 L NO20083856 L NO 20083856L NO 20083856 A NO20083856 A NO 20083856A NO 20083856 A NO20083856 A NO 20083856A NO 20083856 L NO20083856 L NO 20083856L
- Authority
- NO
- Norway
- Prior art keywords
- heteroaryl
- formula
- cxcr3 receptor
- receptor antagonists
- piperidine derivatives
- Prior art date
Links
- 108010061300 CXCR3 Receptors Proteins 0.000 title abstract 2
- 102000011963 CXCR3 Receptors Human genes 0.000 title abstract 2
- 150000003053 piperidines Chemical class 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- -1 heteroaryl-NH- Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Foreliggende oppfinnelse angår en forbindelse med formel (I) et N-oksid derav, et farmasøytisk akseptabelt salt derav, en stereokjemisk isomer form derav eller et solvat derav, hvori X representerer N eller CH; Y representerer en direkte binding, CH2-C(=O) hvori CH2 er bundet til N til piperidinringen, C(=O) eller S(=O)p; p representerer et heltall på 1 eller 2; R1 representerer CH(R4)-aryl eller CH(R4)-heteroaryl; R2 representerer aryl2 eller heteroaryl; R3 representerer hydrogen, C1-6alkyl, polyhaloC1-6alkyl, C1-6alkyloksy, aryl1, aryl1-NH-, heteroaryl, heteroaryl-NH-, C3-7sykloalkyl, amino eller mono eller di(C1-4alkyl)amino. Foreliggende oppfinnelse angår også anvendelsen av en forbindelse med formel (I) for fremstilling av et medikament for hindring eller behandling av en sykdom mediert gjennom aktivering av CXCR3 reseptoren; fremgangsmåter for fremstilling av forbindelsene med formel (I) og farmasøytiske sammensetninger som innbefatter dem.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06101551 | 2006-02-10 | ||
| PCT/EP2007/051123 WO2007090836A2 (en) | 2006-02-10 | 2007-02-06 | Piperidine derivatives as cxcr3 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20083856L true NO20083856L (no) | 2008-11-04 |
Family
ID=35911097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20083856A NO20083856L (no) | 2006-02-10 | 2008-09-08 | Piperidinderivater som CXCR3-reseptorantagonister |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1983986A2 (no) |
| JP (1) | JP2009526016A (no) |
| KR (1) | KR20080093040A (no) |
| CN (1) | CN101378756A (no) |
| AR (1) | AR059427A1 (no) |
| AU (1) | AU2007213744A1 (no) |
| BR (1) | BRPI0707629A2 (no) |
| CA (1) | CA2635138A1 (no) |
| EA (1) | EA200870246A1 (no) |
| IL (1) | IL193295A0 (no) |
| NO (1) | NO20083856L (no) |
| TW (1) | TW200811131A (no) |
| WO (1) | WO2007090836A2 (no) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140329809A1 (en) | 2011-10-28 | 2014-11-06 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE632403A (no) * | 1962-05-17 | 1900-01-01 | ||
| ATE319703T1 (de) * | 2001-07-02 | 2006-03-15 | Piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen |
-
2007
- 2007-02-06 CN CNA2007800049228A patent/CN101378756A/zh active Pending
- 2007-02-06 AU AU2007213744A patent/AU2007213744A1/en not_active Abandoned
- 2007-02-06 CA CA002635138A patent/CA2635138A1/en not_active Abandoned
- 2007-02-06 KR KR1020087019298A patent/KR20080093040A/ko not_active Withdrawn
- 2007-02-06 BR BRPI0707629-0A patent/BRPI0707629A2/pt not_active Application Discontinuation
- 2007-02-06 JP JP2008553749A patent/JP2009526016A/ja not_active Withdrawn
- 2007-02-06 WO PCT/EP2007/051123 patent/WO2007090836A2/en not_active Ceased
- 2007-02-06 EP EP07726319A patent/EP1983986A2/en not_active Withdrawn
- 2007-02-06 EA EA200870246A patent/EA200870246A1/ru unknown
- 2007-02-09 TW TW096104683A patent/TW200811131A/zh unknown
- 2007-02-09 AR ARP070100558A patent/AR059427A1/es unknown
-
2008
- 2008-08-07 IL IL193295A patent/IL193295A0/en unknown
- 2008-09-08 NO NO20083856A patent/NO20083856L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007090836A3 (en) | 2007-11-29 |
| KR20080093040A (ko) | 2008-10-17 |
| EP1983986A2 (en) | 2008-10-29 |
| TW200811131A (en) | 2008-03-01 |
| BRPI0707629A2 (pt) | 2011-05-10 |
| EA200870246A1 (ru) | 2009-02-27 |
| WO2007090836A2 (en) | 2007-08-16 |
| AU2007213744A1 (en) | 2007-08-16 |
| JP2009526016A (ja) | 2009-07-16 |
| AR059427A1 (es) | 2008-04-09 |
| IL193295A0 (en) | 2009-08-03 |
| CA2635138A1 (en) | 2007-08-16 |
| CN101378756A (zh) | 2009-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2423207A3 (en) | 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors | |
| NO20072371L (no) | Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister | |
| WO2012146724A3 (en) | Novel rock inhibitors | |
| SE0400284D0 (sv) | Novel compounds | |
| EA201101398A1 (ru) | Замещенные пиперидины в качестве антагонистов ccr3 | |
| AR074359A1 (es) | Compuestos heterociclicos sustituidos como moduladores de canales ionicos | |
| NO20083909L (no) | Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere | |
| NO20075624L (no) | Nye histamin H3-reseptorligander og deres terapeutiske anvendelser | |
| AR044543A1 (es) | Derivados de pirazolo-quinazolina, un procedimiento para su preparacion y su uso como inhibidor de quinasa | |
| NO20076060L (no) | Piperidin-4-yl-amidderivater og deres anvendelse som SST-reseptor subtype 5-antagonister | |
| PH12019550083A1 (en) | Inhibitors of bruton's tyrosine kinase | |
| NO20071314L (no) | Peptidiske vasopressinreseptoragonister | |
| TW200724136A (en) | Pharmaceutical compositions comprising PPAR modulator | |
| NO20085107L (no) | Spirosykliske nitriler som proteaseinhibitorer | |
| EA200801909A1 (ru) | Соединения пиридина для лечения заболеваний, опосредованных действием простагландина | |
| TW200616979A (en) | Non-nucleoside reverse transcriptase inhibitors | |
| AR077534A1 (es) | Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5 | |
| NO20091486L (no) | Nye imidazolonderivater, deres fremstilling som medikamenter, farmasoytiske preparater og anvendelse derav som proteinkinaseinhibitorer, saerlig CDC7 | |
| EA200801134A1 (ru) | Замещенные бициклические пиримидоновые производные | |
| AR061185A1 (es) | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. | |
| MY183288A (en) | Novel octahydrothienoquinoline derivative, pharmaceutical composition comprising derivative, and use of these | |
| DK1723138T3 (da) | Substituerede benzimidazoler og deres anvendelse til at inducere apoptose | |
| MX2011007272A (es) | Piperidinas de aroilamino y heteroaroilamino sustituidas como inhibidores de glyt-1. | |
| NO20083856L (no) | Piperidinderivater som CXCR3-reseptorantagonister | |
| NO20083857L (no) | Piperidinderivater som CXCR3-reseptorantagonister |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |